Safe, simple and multifunctional hydroxyapatite nanoparticles for efficient overcoming of tumor multidrug resistance
Bibliographic record
Abstract
No abstract is available for this record. The assistant can identify its topic from the title, but cannot infer the study’s results.
Source: Not provided · Quality: missing
Research context
OpenAlex topics: Nanoparticle-Based Drug Delivery · Nanoplatforms for cancer theranostics · Graphene and Nanomaterials Applications
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
References (76)
Show source-provided references
1. Cancer statistics for the year 2020: an overview10.1002/ijc.33588 ↗
2. Global cancer statistics 2022: the trends projection analysis
3. Mechanisms of multidrug resistance in cancer chemotherapy10.3390/ijms21093233 ↗
4. Drug resistance in cancer: mechanisms and tackling strategies10.1007/s43440-020-00138-7 ↗
5. Overcoming drug-resistant lung cancer by paclitaxel loaded tetrahedral DNA nanostructures10.1039/C7NR09692E ↗
6. Difunctional pluronic copolymer micelles for paclitaxel delivery: synergistic effect of folate-mediated targeting and Pluronic-mediated overcoming multidrug resistance in tumor cell lines10.1016/j.ijpharm.2006.12.033 ↗
7. Tumor- and mitochondria-targeted nanoparticles eradicate drug resistant lung cancer through mitochondrial pathway of apoptosis10.1186/s12951-019-0562-3 ↗
8. Doxorubicin and edelfosine combo-loaded lipid–polymer hybrid nanoparticles for synergistic anticancer effect against drug-resistant osteosarcoma10.2147/OTT.S259428 ↗
9. Development of high-drug-loading nanoparticles10.1002/cplu.202000496 ↗
10. The reversal of chemotherapy-induced multidrug resistance by nanomedicine for cancer therapy10.1016/j.jconrel.2021.05.012 ↗
11. Novel nanomedicines to overcome cancer multidrug resistance10.1016/j.drup.2021.100777 ↗
12. Self-targeting visualizable hyaluronate nanogel for synchronized intracellular release of doxorubicin and cisplatin in combating multidrug-resistant breast cancer10.1007/s12274-020-3124-y ↗
13. Co-delivery of doxorubicin and paclitaxel by reduction/pH dual responsive nanocarriers for osteosarcoma therapy10.1080/10717544.2020.1785049 ↗
14. Co-delivery of paclitaxel and curcumin by biodegradable polymeric nanoparticles for breast cancer chemotherapy10.1016/j.ijpharm.2020.119875 ↗
15. Cancer nanomedicine: progress, challenges and opportunities10.1038/nrc.2016.108 ↗
16. New challenges in the use of nanomedicine in cancer therapy10.1080/21655979.2021.2012907 ↗
17. Synergistic combination of bioactive hydroxyapatite nanoparticles and the chemotherapeutic doxorubicin to overcome tumor multidrug resistance10.1002/smll.202007672 ↗
18. Recent advances in biomedical engineering of nano-hydroxyapatite including dentistry, cancer treatment and bone repair10.1016/j.compositesb.2021.108790 ↗
19. Dual-functional scaffolds of poly(L-lactic acid)/nanohydroxyapatite encapsulated with metformin: simultaneous enhancement of bone repair and bone tumor inhibition10.1016/j.msec.2020.111592 ↗
20. Multifunctional hydroxyapatite composites for orthopedic applications: a review10.1021/acsbiomaterials.2c00140 ↗
21. Nano hydroxyapatite induces glioma cell apoptosis by suppressing NF‑κB signaling pathway
22. The cytotoxicity of carbon nanotubes and hydroxyapatite, and graphene and hydroxyapatite nanocomposites against breast cancer cells10.3390/nano13030556 ↗
23. Mitochondria-targeted hydroxyapatite nanoparticles for selective growth inhibition of lung cancer in vitro and in vivo10.1021/acsami.6b06094 ↗
24. A selective reduction of osteosarcoma by mitochondrial apoptosis using hydroxyapatite nanoparticles10.2147/IJN.S375950 ↗
25. Effects of hydroxyapatite nanoparticles on proliferation and apoptosis of human breast cancer cells (MCF-7)10.1007/s11051-011-0712-5 ↗
26. Hydroxyapatite nanoparticles inhibit the growth of human glioma cells in vitro and in vivo10.2147/IJN.S33584 ↗
27. Size-mediated cytotoxicity and apoptosis of hydroxyapatite nanoparticles in human hepatoma HepG2 cells10.1016/j.biomaterials.2009.09.088 ↗
28. Differential cytotoxicity and particle action of hydroxyapatite nanoparticles in human cancer cells10.2217/nnm.12.217 ↗
29. Correlation ofparticle properties with cytotoxicity and cellular uptake of hydroxyapatite nanoparticles in human gastric cancer cells10.1016/j.msec.2016.05.034 ↗
30. Hydroxyapatite nanoparticles induced calcium overload-initiated cancer cell-specific apoptosis through inhibition of PMCA and activation of calpain10.1039/D3TB00542A ↗
31. Sustained delivery of gambogic acid from mesoporous rod-structure hydroxyapatite for efficient in vitro cancer therapy10.1016/j.bioadv.2022.212821 ↗
32. 5-fluorouracil and curcuminoids extract from Curcuma longa L. loaded into nanohydroxyapatite as a drug delivery carrier for SKOV-3 and HepG2 cancer cells treatment10.1016/j.ceramint.2023.05.123 ↗
33. Bone mineral: a trojan horse for bone cancers. Efficient mitochondria targeted delivery and tumor eradication with nano hydroxyapatite containing doxorubicin
34. DOX-loaded hydroxyapatite nanoclusters for colorectal cancer (CRC) chemotherapy: evaluation based on the cancer cells and organoids10.1016/j.slast.2022.10.002 ↗
35. Paclitaxel-loaded hydroxyapatite/collagen hybrid gels as drug delivery systems for metastatic cancer cells10.1016/j.ijpharm.2013.02.002 ↗
36. Design and characterization of a novel pH-sensitive biocompatible and multifunctional nanocarrier for in vitro paclitaxel release10.1016/j.msec.2020.111627 ↗
37. Drug combination studies and their synergy quantification using the chou-talalay method10.1158/0008-5472.CAN-09-1947 ↗
38. Synergistic suppression of human breast cancer cells by combination of plumbagin and zoledronic acid in vitro10.1038/aps.2015.42 ↗
39. Combination of tetrandrine and cisplatin synergises cytotoxicity and apoptosis in triple negative breast cancer10.1016/j.synres.2020.100063 ↗
40. The combination index (CI < 1) as the definition of synergism and of synergy claims10.1016/j.synres.2018.04.001 ↗
41. Paclitaxel/hydroxyapatite composite coatings on titanium alloy for biomedical applications10.1016/j.msec.2017.04.159 ↗
42. In vitro assessment of cellular responses to rod-shaped hydroxyapatite nanoparticles of varying lengths and surface areas10.3109/17435390.2010.503943 ↗
43. Preparation of paclitaxel/chitosan co-assembled core-shell nanofibers for drug-eluting stent10.1016/j.apsusc.2016.10.015 ↗
44. Preparation and characterization of paclitaxel/chitosan nanosuspensions for drug delivery system and cytotoxicity evaluation in vitro10.1007/s42765-019-00012-z ↗
45. Preparation, characterization and in vitro cytotoxicity of paclitaxelloaded sterically stabilized solid lipid nanoparticles10.1016/j.biomaterials.2007.01.014 ↗
46. Preparation and physicochemical characterization of a novel paclitaxel-loaded amphiphilic aminocalixarene nanoparticle platform for anticancer chemotherapy10.1111/j.2042-7158.2012.01518.x ↗
47. Different inhibitory effect and mechanism of hydroxyapatite nanoparticles on normal cells and cancer cells in vitro and in vivo10.1038/srep07134 ↗
48. A novel strategy for tumor therapy: targeted, PAA-functionalized nano-hydroxyapatite nanomedicine10.1039/D0TB01603A ↗
49. Drug resistance in cancer: an overview10.3390/cancers6031769 ↗
50. Paclitaxel-induced apoptosis in human gastric carcinoma cell lines10.1002/(SICI)1097-0142(19960101)77:1<14::AID-CNCR4>3.0.CO;2-N ↗
51. Doxorubicin exerts cytotoxic effects through cell cycle arrest and fas-mediated cell death10.1159/000245937 ↗
52. Mechanism of apoptosis induced by doxorubicin through the generation of hydrogen peroxide10.1016/j.lfs.2004.05.040 ↗
53. Paclitaxel-induced apoptosis in MCF-7 breast-cancer cells10.1002/(SICI)1097-0215(19970117)70:2<214::AID-IJC13>3.0.CO;2-I ↗
54. Calcium-chelated nanosystem reversing cancer chemoresistance via replenishing intracellular calcium ions10.1016/j.cej.2022.137500 ↗
55. Synergistic effect of paclitaxel and verapamil to overcome multi-drug resistance in breast cancer cells10.1016/j.bbrc.2019.05.189 ↗
56. ATP-binding cassette efflux transporters and MDR in cancer10.1016/j.drudis.2023.103537 ↗
57. Molecular avenues in targeted doxorubicin cancer therapy10.2217/fon-2019-0458 ↗
58. Mechanism of action of dna topoisomerase inhibitors10.1002/stem.5530130408 ↗
59. Detection of histone h2ax phosphorylation on ser-139 as an indicator of dna damage10.1002/cpcy.55 ↗
60. Non-p-glycoprotein-mediated multidrug resistance in a small cell lung cancer cell line: evidence for decreased susceptibility to drug-induced dna damage and reduced levels of topoisomerase ii
61. MiR-7-5p-mediated downregulation of PARP1 impacts DNA homologous recombination repair and resistance to doxorubicin in small cell lung cancer10.1186/s12885-019-5798-7 ↗
62. Mechanisms of cancer cell death induction by paclitaxel: an updated review10.1007/s10495-022-01750-z ↗
63. Taxol cytotoxicity on human leukemia cell lines is a function of their susceptibility to programmed cell death10.1007/BF00686187 ↗
64. Taxol-induced polymerization of purified tubul10.1016/S0021-9258(19)68639-4 ↗
65. Enhancement of paclitaxel-induced microtubule stabilization, mitotic arrest, and apoptosis by the microtubule-targeting agent EM01210.1016/j.bcp.2004.08.032 ↗
66. Paclitaxel enhances the innate immunity by promoting nlrp3 inflammasome activation in macrophages10.3389/fimmu.2019.00072 ↗
67. Evaluation of p-glycoprotein inhibitory potential using a rhodamine 123 accumulation assay10.3390/pharmaceutics8020012 ↗
68. Mitochondrial ATP fuels ABC transporter-mediated drug efflux in cancer chemoresistance10.1038/s41467-021-23071-6 ↗
69. ATP-binding cassette (ABC) transporters in cancer: a review of recent updates10.1111/jebm.12434 ↗
70. Antitumor effect by hydroxyapatite nanospheres: activation of mitochondriadependent apoptosis and negative regulation of phosphatidylinositol-3-kinase/protein kinase b pathway10.1021/acsnano.8b01996 ↗
71. Hydroxyapatite nanocomposite as a potential agent in osteosarcoma PDT10.1016/j.pdpdt.2020.102056 ↗
72. Caspase-9, caspase-3 and caspase-7 have distinct roles during intrinsic apoptosis10.1186/1471-2121-14-32 ↗
73. Caspase- 8: regulating life and death10.1111/imr.12541 ↗
74. Doxorubicin changes Bax /Bcl-xl ratio, caspase-8 and 9 in breast cancer cells10.15171/apb.2015.049 ↗
75. Paclitaxel induces apoptosis via caspase-3 activation in human osteogenic sarcoma cells (U-2 0s)10.1016/j.orthres.2005.01.018 ↗
76. Paclitaxel promotes a caspase 8-mediated apoptosis through death effector domain association with microtubules10.1038/onc.2009.210 ↗